TICKERNERD
Menu
BIOABIOAHealthcare · Drug Manufacturers - Specialty & Generic

BIOA Stock Forecast: BioAge Labs, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$9.48
−2.17% on the day

The 9 Wall Street analysts covering BioAge Labs, Inc. hold a median 12-month price target of $30 — +216.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$435.1M
Ticker Nerd rank
41 / 100
Median analyst target
$30
Analysts covering
9
Total return, dividends reinvested
1W
−10.6%
1M
−58.1%
YTD
−28.3%
1Y
+110.7%
From 52W high
−62.2%
From 52W low
+110.7%
$5
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BIOA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioAge Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
74
Revisions
72
Growth
61
Size
56
Issuance
52
Accruals
30
Quality
26
Value
24
Volatility
14

Momentum (74): The shares have been drifting up relative to others.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIOA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIOA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26BIOAHigh $73Median $30Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
7 Buy2 Hold0 Sell
Low $20Median $30High $73

The green dot is the last close — the median target sits +216.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Aug 2026BTIGReiteratesBuy—
6 Aug 2026BTIGReiteratesBuy$40
3 Aug 2026BTIGReiteratesBuy—
3 Aug 2026BTIGReiteratesBuy$40
31 July 2026NeedhamMaintainsBuy—
31 July 2026NeedhamMaintainsBuy$50 → $35
27 May 2026Roth CapitalInitiatesBuy$36
27 May 2026Roth CapitalInitiatesBuy—
13 May 2026BTIGInitiatesBuy—
27 Mar 2026NeedhamInitiatesBuy—
10 Mar 2026CitigroupMaintainsBuy—
25 Feb 2026OppenheimerInitiatesOutperform—
18 Feb 2026JefferiesUpgradeBuy—
27 Jan 2026Piper SandlerInitiatesOverweight—
8 Dec 2025Morgan StanleyUpgradeEqual-Weight—
29 Oct 2025CitigroupMaintainsBuy—
22 Oct 2025CitigroupUpgradeBuy—
24 Mar 2025CitigroupMaintainsNeutral—
7 Mar 2025Morgan StanleyAssumesUnderweight$5.00
28 Feb 2025William BlairInitiatesMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIOA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BIOA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

BioAge Labs, Inc. (BIOA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.4×

Cheaper than 70% of US stocks

Price / sales
42.0×

Cheaper than 6% of US stocks

Price / book
1.2×

Cheaper than 69% of US stocks

EV / EBITDA
−1.1×

Cheaper than 67% of US stocks

Growth & margins
Revenue growth (YoY)
1.6%

Higher than 31% of US stocks

Earnings growth (YoY)
1.6%

Higher than 38% of US stocks

Gross margin
—
Operating margin
−1196.8%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−28.2%

Higher than 27% of US stocks

Return on assets
−18.5%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BIOA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BIOABioAge Labs, Inc.$435.1M
41
TKNOAlpha Teknova, Inc.$394.6M
93
CGCCanopy Growth Corp.$474.5M
48
KMDAKamada Ltd.$483.3M
95
EOLSEvolus, Inc.$545.9M
87
AQSTAquestive Therapeutics, Inc.$584.9M
50
ANIKAnika Therapeutics, Inc.$291.9M
100

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioAge Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIOA news & analysis

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 6 Aug 2026positive

BioAge Labs reported a quarterly loss of $0.58 per share for Q2, narrower than the Zacks Consensus Estimate of a $0.65 loss and slightly better than the $0.6 per-share loss a year ago. The company also beat revenue estimates.

Why it matters — A BIOA watcher would care because the company's quarterly loss came in better than analyst expectations, indicating results were stronger than consensus forecast.

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewsWire · 5 Aug 2026neutral

BioAge Labs reported its second quarter 2026 financial results and provided business updates. The update noted that the first participant has been dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers, with topline data anticipated in the second half of 2026.

Why it matters — The QueLL-CV trial enrollment start for BGE-102 and the expected topline readout in the second half of 2026 represent a key upcoming clinical milestone for BIOA watchers.

Why Is BioAge Labs Stock Sinking Friday?

Benzinga · 31 July 2026negative

BioAge Labs stock fell Friday after Novo Nordisk reported disappointing Phase 3 cardiovascular trial results, raising concerns about the potential of NLRP3-targeting therapies.

Why it matters — A BIOA watcher would care because the negative read-through from Novo Nordisk's trial outcome may reflect on the broader prospects for the NLRP3-targeting approach that BioAge Labs is involved with.

FAQ

Frequently asked questions about BIOA stock

What is the BIOA stock price forecast for 2026-2027?

The 9 Wall Street analysts covering BioAge Labs, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BIOA stock a buy right now?

Of the 9 analysts covering BioAge Labs, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioAge Labs, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIOA?

As at 22 Aug 2026, BioAge Labs, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (74 of 100).

Will BIOA stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +216.5% from the last close, and Ticker Nerd's factor model ranks BioAge Labs, Inc. 41 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BIOA stock forecast for 2030?

No analyst covering BioAge Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIOA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $73 over the next 12 months.

How has BIOA stock performed over the past year?

BioAge Labs, Inc. returned +110.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioAge Labs, Inc. do?

BioAge Labs Inc. is a biotechnology company focused on discovering and developing therapies that can enhance the human lifespan and address age-related diseases.

What is the latest news on BIOA?

The most recent item we track (Zacks Investment Research, 6 Aug 2026): "BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates". BioAge Labs reported a quarterly loss of $0.58 per share for Q2, narrower than the Zacks Consensus Estimate of a $0.65 loss and slightly better than the $0.6 per-share loss a year ago. The company also beat revenue estimates.

Company

About BioAge Labs, Inc.

BioAge Labs Inc. is a biotechnology company focused on discovering and developing therapies that can enhance the human lifespan and address age-related diseases. By leveraging advanced technologies like artificial intelligence and genomics, BioAge Labs aims to pinpoint key molecular drivers of aging. Its approach involves identifying biological pathways that extend healthy lifespan, then discovering compounds that can influence these pathways to develop innovative treatments for age-associated conditions such as cancer, cardiovascular diseases, and metabolic disorders. BioAge Labs conducts research that spans various stages, from preclinical studies to early-stage clinical trials, frequently collaborating with leading scientific institutions and pharmaceutical partners. Operating within the biopharmaceutical industry, the company's work significantly impacts healthcare and wellness sectors by potentially altering age-related disease progression and improving quality of life for aging populations. As part of the burgeoning field of biotechnology focusing on longevity, BioAge Labs holds a notable place in the financial market by engaging in an area of medicine that combines cutting-edge bioinformatics with traditional biopharmaceutical research and development.

CEO Dr. Kristen Fortney Ph.D. · 60 employees · United States · https://bioagelabs.com